Skip to main content
Elsevier
View Cart
My account

Books in Pharmaceutical sciences

Elsevier's Pharmaceutical Sciences collection helps pharmaceutical scientists striving to optimize drug design and improve healthcare outcomes by offering comprehensive coverage of every aspect of drug development, integrating disciplines like organic chemistry, biology, and biotechnology. Focused on safety, efficacy, and formulation design, it includes specialized fields such as Clinical Pharmacology and Translational Research, providing valuable insights into the latest advancements in drug discovery.

BooksJournals

    • Handbook of Non-Invasive Drug Delivery Systems

      • 1st Edition
      • April 1, 2000
      • Vitthal S. Kulkarni
      • English
      • Hardback
        9 7 8 0 8 1 5 5 2 0 2 5 2
      • eBook
        9 7 8 0 8 1 5 5 2 0 2 6 9
      • eBook
        9 7 8 0 0 8 0 9 5 1 8 7 4
      With the improvements in formulation science and certain transdermal delivery technologies, the non-invasive mode of drug delivery is now ready to compete with traditional methods of oral and injectible routes of drug delivery. The Handbook of Non-Invasive Drug Delivery Systems encompasses the broad field of non-invasive drug delivery systems that include drug delivery via topical, transdermal-passive, transdermal-active (device- aided enhanced penetration), trans-mucosal membrane, trans-ocular membrane as well as delivery via alveolar membrane from inhaled medication. Patient compliance has been found to be much higher when administrated by non-invasive routes and therefore they are considered to be a preferred mode of drug delivery. The book includes both science and technological aspects of new drug delivery systems. Its unique focus is that it is on new drug delivery systems that are considered to be "non-invasive". Other unique features include a chapter on Regulatory Aspects of non-invasive systems and one on FDA guidance for topical nano-drug delivery. Two chapters covering market trends and perspectives, as well as providing guidance to those marketing such systems are also included.

    • Advances in Pharmacology

      • 1st Edition
      • Volume 46
      • May 5, 1999
      • English
      • Paperback
        9 7 8 0 1 2 3 9 1 7 6 0 7
      • Hardback
        9 7 8 0 1 2 0 3 2 9 4 7 2
      • eBook
        9 7 8 0 0 8 0 5 8 1 3 8 5
      Each volume of Advances in Pharmacology provides a rich collection of reviews on timely topics. Emphasis is placed on the molecular bases of drug action, both applied and experimental.

    • Analytical Profiles of Drug Substances and Excipients

      • 1st Edition
      • Volume 26
      • October 5, 1999
      • English
      • Paperback
        9 7 8 0 1 2 3 9 1 8 0 4 8
      • Hardback
        9 7 8 0 1 2 2 6 0 8 2 6 1
      • eBook
        9 7 8 0 0 8 0 8 6 1 2 1 0
      Although the official compendia define a drug substance as to identity, purity, strength, and quality, they normally do not provide other physical or chemical data, nor do they list methods of synthesis or pathways of physical or biological degradation and metabolism. Such information is scattered throughout the scientific literature and the files of pharmaceutical laboratories. Edited by the Associate Director of Analytical Research and Development for the American Association of Pharmaceutical Scientists, Analytical Profiles of Drug Substances and Excipients brings this information together into one source. The scope of the series has recently been expanded to include profiles of excipient materials.

    • Advances in Antiviral Drug Design

      • 1st Edition
      • Volume 3
      • November 22, 1999
      • E. De Clercq
      • English
      • Paperback
        9 7 8 0 4 4 4 5 4 3 6 0 8
      • Hardback
        9 7 8 0 7 6 2 3 0 2 0 1 7
      • eBook
        9 7 8 0 0 8 0 5 2 6 0 4 1
      Volume 3 of Advances in Antiviral Drug Design is keeping up with the recent progress made in the field of antiviral drug research and highlights five specific directions that have opened new avenues for the treatment of virus infections. First, the use of lamivudine (3TC) for the treatment of HIV infections, and its more recent introduction for the treatment of hepatitis B virus (HBV) infections, has heralded the transition of D- to L-nucleosides in the antiviral nucleoside drug design, and it is likely that the future will provide more nucleosides of the L-configuration, such as (-)FFC (emtricitabine) and L-FMAU, as will be described by J.-C.G. Graciet and R.F. Shinazi. Second, the acyclic purine nucleoside phosphonates, i.e. PMEA (adefovir and PMPA (tenofovir), offer great potential as both anti-HIV and anti-HBV agents, and both compounds have been the subject of advanced clinical trials in their oral produrg form (adefovir dipivoxil and tenofovir disoproxyl), as mentioned by M.N. Arimilli, J.P. Dougherty, K.C. Cundy, and N. Bischofberger.Third, with the advent of nevirapine, delavirdine, and efavirenz, the NNRTIs have definitely come of age. Emivirine (MKC-442), a derivative of the original HEPT analog that was described in 1989 has now proceeded through pivotal clinical studies, and how this class of compounds evolved is presented in the account of H. Tanaka and his colleagues. Fourth, at the end of 1999, anticipating on the next winter influenza offensive, we should have at end two compounds that specifically inhibit influenza A and B virus infections: zanamivir (by the intranasal route) and oseltamivir (by the oral route). Both compounds have proved effective in the prophylaxis and treatment of influenza A and B virus infections and act through the same mechanism; that is by blocking the viral neuraminidase (or sialidase), a key enzyme that allows the virus to spread from one cell to another (within the respiratory mucosal tract). The design of these sialidase inhibitors will be presented by M. von Itzstein and J.C. Dyason.Fifth, the discovery (in 1996) of the chemokine receptors CXCR4 and CCR5 as essential coreceptors (in addition to the CD4 receptor) for HIV entry into the cells, has boosted an enormous interest in potential antagonists of these receptors. The bicyclams represent the first low-molecular-weight compounds targeted at CXCR4, the coreceptor used by the more pathogenic, T-lymphotropic, HIV strains, to enter the cells. They will be addressed by G.J. Bridger and R.T. Skerlj.The five topics covered in this third volume of Advances in Antiviral Drug Design are in the front line of the present endeavors towards the chemotherapy of virus infections. They pertain to the combat against three of the most important virus infections of current times: HIV, HBV, and influenza virus.

    • Advances in Medicinal Chemistry

      • 1st Edition
      • Volume 4
      • April 1, 1999
      • B.E. Maryanoff + 1 more
      • English
      • Hardback
        9 7 8 0 7 6 2 3 0 0 6 4 8
      • Paperback
        9 7 8 0 4 4 4 5 4 6 4 9 4
      • eBook
        9 7 8 0 0 8 0 5 2 6 3 7 9
      Volume 4 of Advances in Medicinal Chemistry is comprised of six chapters on a wide range of topics in medicinal chemistry, including molecular modeling, structure-based drug design, organic synthesis, peptide conformational analysis, biological assessment, structure-activity correlation, and lead optimization. Chapter 1 presents an account about amino acid-based peptide mimetics corresponding to b-turn, loop, helical motifs in proteins as a probe of ligand-receptor and ligand-enzyme molecular interactions. Chapter 2 addresses new facets of the medicinal chemistry of the important anticancer drug Taxol® (paclitaxel). Chapter 3 relates an account of the search for new drugs for the treatment of malaria based on the natural product artemisinin. Chapter 4 applies computational chemistry to the evaluation of compound libraries for biological testing. Chapter 5 describes the construction of a 3-dimensional molecular model of the human thrombin receptor, the first protease-activated G-protein coupled receptor (PAR-1), as a means to explore the intermolecular contacts involved in agonist peptide recognition. Finally, Chapter 6 describes the research conducted at Merck on inhibitors of farnesyl transferase as a potential treatment for human cancers.

    • Analytical Profiles of Drug Substances and Excipients

      • 1st Edition
      • Volume 25
      • March 2, 1998
      • English
      • Paperback
        9 7 8 0 1 2 3 9 1 8 0 3 1
      • Hardback
        9 7 8 0 1 2 2 6 0 8 2 5 4
      • eBook
        9 7 8 0 0 8 0 8 6 1 2 0 3
      Although the official compendia define a drug substance as to identity, purity, strength, and quality, they normally do not provide other physical or chemical data, nor do they list methods of synthesis or pathways of physical or biological degradation and metabolism. Such information is scattered throughout the scientific literature and the files of pharmaceutical laboratories. Edited by the Associate Director of Analytical Research and Development for the American Association of Pharmaceutical Scientists, Analytical Profiles of Drug Substances and Excipients brings this information together into one source. The scope of the series has recently been expanded to include profiles of excipient materials.

    • Medical Applications of Liposomes

      • 1st Edition
      • July 22, 1998
      • D.D. Lasic + 1 more
      • English
      • Hardback
        9 7 8 0 4 4 4 8 2 9 1 7 7
      • eBook
        9 7 8 0 0 8 0 5 3 6 0 8 8
      The development of liposomes as a drug delivery system has fluctuated since its introduction in the late 1960's by A.D. Bangham. While academic research of liposomes as a model membrane system has always flourished, as the exponential growth of papers can testify, the application of these findings to medically useful products has gone through several crises. Following the original optimism in the 70's and early 80's, a period of severe skepticism ensued at the end of the 80's and beginning of the 90's, culminating in a moderate but real optimism in the mid 90's, as a result of a successful launch of the first products in the US and Europe.In this collection of papers, the editors have gathered the most promising ideas, approaches, applications and commercial developments, thereby presenting an up-to-date compilation of the present status of the field. This includes such broad areas as anti-cancer chemotherapy immune stimulation and infectious diseases. Currently, the major areas of progress are in delivery of anti-fungal agents by conventional liposomes or lipid-based carriers and systemic anticancer therapy using long-circulating liposomes. The future applications as characterized by the direction of present day research is in specific targeting and delivery of informational molecules such as DNA plasmids (genes), antisense oligonucleotides or ribozymes. Other future developments may be in topical delivery, vaccination and in diagnostics.Features of this book:• Contributions from almost all the leading labs in the field• Up-to-date, critical reviews bridged by editors' introductions• Organized into a logical framework.

    • New Cosmetic Science

      • 1st Edition
      • June 19, 1997
      • T. Mitsui
      • English
      • eBook
        9 7 8 0 0 8 0 5 3 7 4 9 8
      Cosmetic science covers the fields from natural sciences to human and social sciences, and is an important interdisciplinary element in various scientific disciples. New Cosmetic Science is a completely updated comprehensive review of its 35 year old counterpart Cosmetic Science. New Cosmetic Science has been written to give as many people as possible a better understanding of the subject, from scientists and technologists specializing in cosmetic research and manufacturing, to students of cosmetic science, and people with a wide range of interests concerning cosmetics.The relationship between the various disciplines comprising cosmetic science, and cosmetics, is described in Part I. In addition to discussing the safety of cosmetics, the "Usefulness of Cosmetics", rapidly becoming an important theme, is described using research examples. The latest findings on cosmetic stability are presented, as are databases, books and magazines, increasingly used by cosmetic scientists. Part II deals with cosmetics from a usage viewpoint, including skin care cosmetics, makeup cosmetics, hair care cosmetics, fragrances, body cosmetics, and oral care cosmetics. Oral care cosmetics and body cosmetics are presented with product performance, types, main components, prescriptions and manufacturing methods described for each item.This excellent volume enlightens the reader not only on current cosmetics and usage, but indicates future progress enlarging the beneficial effects of cosmetics. Products with better pharmaceutical properties (cosmeceuticals), working both physically and psychologically, are also highlighted.

    • Approaches to Design and Synthesis of Antiparasitic Drugs

      • 1st Edition
      • Volume 25
      • July 10, 1997
      • N. Anand + 1 more
      • English
      • Paperback
        9 7 8 0 4 4 4 5 5 1 3 5 1
      • Hardback
        9 7 8 0 4 4 4 8 9 4 7 6 2
      • eBook
        9 7 8 0 0 8 0 5 2 7 5 2 9
      This book presents a comprehensive and up to date account of the chemotherapy of parasitic diseases, both human and veterinary. The book starts with an overview of parasitic diseases. The body of the book is divided into two parts: antihelminthic drugs, and antiprotozoal drugs. Both parts start with chapters highlighting the 'biochemical targets' available for chemotherapeutic interference. Individual chapters deal with one chemical class of compounds and describe their origin, structure-activity relationship, mode of action, and methods of synthesis and their status both in clinical and veterinary practice. The book will be useful to a wide spectrum of readers: students embarking on a research career in parasitic chemotherapy, clinicians (and veterinarians) and clinical pharmacologists desiring detailed information about the drugs currently in use, and pharmaceutical technologists wanting to update their knowledge of the methods of manufacture.

    • The Many Faces of RNA

      • 1st Edition
      • December 19, 1997
      • D. S. Eggleston + 2 more
      • English
      • Hardback
        9 7 8 0 1 2 2 3 3 2 1 0 4
      • Paperback
        9 7 8 0 1 2 3 9 0 9 2 5 1
      • eBook
        9 7 8 0 0 8 0 5 4 2 5 5 3
      The Many Faces of RNA is the subject for the eighth SmithKline Beecham Pharmaceuticals Research Symposia. It highlights a rapidly developing area of scientific investigation. The style and format are deliberately designed to promote in-depth presentations and discussions and to facilitate the forging of collaborations between academic and industrial partners.This symposium focuses on several of the many fundamental, advancing strategies for exploring RNA and its functions. It emphasizes the interplay between biology, chemistry, genomics, and molecular biology which is leading to exciting new insights and avenues of investigation. The book explores RNA as a therapeutic target, RNA as a tool, RNA and its interactions, along with chemical, computational, and structural investigations.

Related subjects

Drug delivery

Drug design

Drug dispensing

Drug manufacturing and packaging

Drug metabolism disposition

Pharmaceutical analysis

Pharmaceutical biotechnology

Pharmaceutical quality control

Pharmaceutical science general

Pharmaceutical technology

Pharmacoeconomics

Pharmacoepidemiology

Pharmacotherapy

Pharmacy

Pharmacy management